Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Bone Peptide Measurement Predicts Fracture Risk

By LabMedica International staff writers
Posted on 28 Aug 2017
Measurement of the peptide fragment that results from in vivo digestion of the periostin protein by the enzyme cathepsin K in blood samples identifies subjects at high risk of bone fracture.

Periostin is a matricellular protein involved in bone formation and bone matrix organization, but it is also produced by other tissues. More...
Its circulating levels have been weakly associated with bone microstructure and prevalent fractures, possibly because periostin measured by the current commercial assays does not specifically reflect bone metabolism.

To improve this situation, investigators at the University of Geneva (Switzerland) developed a new ELISA to measure in blood samples the concentration of the periostin fragment (K-Postn) that results from cathepsin K digestion. Cathepsin K is a protease involved in bone resorption. The enzyme's ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage. The investigators hypothesized that circulating K-Postn levels could be associated with bone fragility.

To test this theory, a total of 695 women (age 65.0 ± 1.5 years), enrolled in the Geneva Retirees Cohort (GERICO), were prospectively evaluated over a period of about five years for the occurrence of low-trauma fractures. The investigators measured serum periostin, K-Postn, and bone turnover markers (BTMs), distal radius and tibia microstructure by HR-pQCT (High Resolution Peripheral Quantitative Computer Tomography), hip and lumbar spine BMD (bone mineral density) by DXA (Dual-energy X-ray absorptiometry), and estimated fracture probability using the Fracture Risk Assessment Tool (FRAX).

Results revealed that 66 women sustained a low-trauma clinical fracture during the follow-up period. Total periostin was not associated with fractures; while in contrast, K-Postn was significantly higher in the fracture versus nonfracture group and associated with fracture risk. After adjustment for BMD, FRAX, bone microstructure, or BTMs, K-Postn remained significantly associated with fracture risk. Furthermore, the performance of the fracture prediction models was improved by adding K-Postn to BMD or FRAX.

Circulating K-Postn predicted risk of fracture independently of BMD, BTMs, and FRAX in postmenopausal women. Therefore, measurement of a periostin fragment resulting from in vivo cathepsin K digestion may help to identify subjects at high risk of fracture.

"The periostin fragments' strong association with incident fractures is largely independent of other bone measures, arguing that they may reflect additional bone properties related to bone quality and strength," said first author Dr. Nicolas Bonnet, a researcher in cell biology at the University of Geneva.

The study was published in the August 2, 2017, online edition of the Journal of Bone and Mineral Research.

Related Links:
University of Geneva


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.